Vir Biotechnology, Inc.
NASDAQ:VIRBiotechnology
-$0.25 today
- Market cap
- $1.57B
- Beta
- 1.64
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.00
Volume 2.15M
Average 1.76M
VIR Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Vir Biotechnology, Inc.NASDAQ: VIR
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents broadly unchanged from a year ago
Cash & equivalents stood at $276.09M at the end of Q1 FY2026, up 0.9% from a year earlier and up 17.9% from the prior quarter. Over 3 fiscal years it compounded at -34.9% a year.
Context
- Cash & equivalents amounted to 26.9% of total assets at the end of Q1 FY2026, up 6.0 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +0.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 234.11M USD
- Year-over-year change
- +5.0%
- 4-year CAGR
- -9.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 234.11M | +5.0% |
| FY2024 | 2024-12-31 | 222.95M | -7.7% |
| FY2023 | 2023-12-31 | 241.58M | -71.5% |
| FY2022 | 2022-12-31 | 848.63M | +144.0% |
| FY2021 | 2021-12-31 | 347.82M | — |
Cash & Equivalents vs competitors
How VIR compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +0.9% is the 4th highest of 10, against a peer median of -13.3%.
- Cash & equivalents amounts to 26.9% of total assets for VIR, versus a peer median of 21.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €9.74B EUR | -5.2% | -17.9% | 47.9% | |
| Sep 2026 | $1.2B USD | +5.6% | -6.8% | 8.9% | |
| Mar 2026 | $276.09M USD | +0.9% | -34.9% | 26.9% | |
| Mar 2026 | $228.36M USD | -13.3% | -43.5% | 21.9% | |
| Jun 2026 | $154.97M USD | +76.0% | -33.5% | 27.8% | |
| Mar 2026 | €105.37M EUR | -31.1% | -27.6% | 28.3% | |
| Mar 2026 | $79.32M USD | -33.6% | -47.1% | 29.7% | |
| Mar 2026 | $34.93M USD | -42.0% | -9.8% | 11.1% | |
| Mar 2026 | $31.12M USD | +32.9% | +3.7% | 13.2% | |
| Mar 2026 | $23.71M USD | -36.1% | -16.4% | 8.6% | |
| Peer median (excluding VIR) | — | -13.3% | -17.9% | 21.9% | |
Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 347.82M | 848.63M | 241.58M | 222.95M | 234.11M |
| Short-term Investments | 360.33M | 1.55B | 1.28B | 682.4M | 228.75M |
| Net Receivables | 773.08M | 0 | 0 | 0 | 3.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.59M | 59.2M | 65.82M | 137.11M | 47.62M |
| Total Current Assets | 1.56B | 2.52B | 1.59B | 1.04B | 514.08M |
| Property, Plant & Equipment (Net) | 130.05M | 188.17M | 167.2M | 122.86M | 117.72M |
| Goodwill | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M |
| Intangible Assets | 33.29M | 32.76M | 22.57M | 8.1M | 7.85M |
| Long-term Investments | 201.39M | 23.93M | 105.28M | 190.02M | 314.58M |
| Tax Assets | 0 | 249.72M | 0 | 0 | 0 |
| Other Non-current Assets | 9.78M | (228.5M) | 18.86M | 18.42M | 31.66M |
| Total Non-current Assets | 391.45M | 283.01M | 330.83M | 356.33M | 488.74M |
| Total Assets | 1.95B | 2.8B | 1.92B | 1.4B | 1B |
| Account Payables | 6.52M | 6.42M | 6.33M | 5.08M | 9.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 8.8M |
| Tax Payables | 6.22M | 15.23M | 149K | 0 | 0 |
| Deferred Revenue | 98.21M | 15.52M | 64.85M | 12.65M | 0 |
| Other Current Liabilities | 0 | 7.65M | 9.35M | 16.06M | 74.21M |
| Total Current Liabilities | 341.24M | 511.03M | 175.41M | 119.66M | 92.82M |
| Long-term Debt | 0 | 0 | 0 | 0 | 89.05M |
| Deferred Tax Liabilities | 18.44M | 3.25M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 3.82M | 53.21M | 1.53M | 0 | 0 |
| Other Non-current Liabilities | 25.36M | 32.8M | 40.22M | 38.63M | (33.38M) |
| Total Non-current Liabilities | 181.18M | 213.1M | 153.42M | 128.77M | 144.73M |
| Total Liabilities | 522.42M | 724.13M | 328.82M | 248.43M | 237.55M |
| Common Stock | 13K | 13K | 13K | 14K | 14K |
| Retained Earnings | (138.6M) | 377.24M | (237.82M) | (759.78M) | (1.2B) |
| Accumulated OCI | (1.1M) | (9.12M) | (815K) | (1.72M) | (2.06M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.43B | 2.08B | 1.59B | 1.15B | 765.28M |
| Total Debt | 137.49M | 127.97M | 124.54M | 97.89M | 186.91M |
| Net Debt | (210.33M) | (720.66M) | (117.04M) | (125.06M) | (47.2M) |
Vir Biotechnology, Inc.
NASDAQ:VIR
Intrinsic Alpha fair value
Locked
Current Price
$9.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.